Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2025 | $34.00 | Outperform | Oppenheimer |
| 5/2/2025 | $25.00 | Buy | Alliance Global Partners |
| 2/28/2025 | $39.00 | Buy | Craig Hallum |
| 7/16/2024 | $25.00 → $30.00 | Buy | Maxim Group |
| 12/22/2022 | $11.00 | Buy | Maxim Group |
| 7/18/2022 | $7.00 | Outperform | Oppenheimer |
| 8/17/2021 | $10.00 → $9.00 | Buy | Aegis Capital |
| 8/11/2021 | $7.00 → $6.50 | Buy | HC Wainwright & Co. |
Submission status for MEDIWOUND, LTD's drug NEXOBRID (SUPPL-10) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 08/15/2024. Application Category: BLA, Application Number: 761192, Application Classification:
Submission status for MEDIWOUND, LTD's drug NEXOBRID (ORIG-1) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761192, Application Classification:
Submission status for MEDIWOUND, LTD's drug NEXOBRID (SUPPL-1) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761192, Application Classification: